JWH-198
From Infogalactic: the planetary knowledge core
220px | |
Systematic (IUPAC) name | |
---|---|
(1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethanone
|
|
Clinical data | |
Legal status |
|
Identifiers | |
CAS Number | 166599-76-4 |
PubChem | CID: 10319620 |
ChemSpider | 8495084 |
Chemical data | |
Formula | C26H26N2O3 |
Molecular mass | 414.495 g/mol |
|
|
|
|
(what is this?) (verify) |
JWH-198 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a binding affinity at the CB1 receptor of 10nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring.[1] It has been used mainly in molecular modelling of the cannabinoid receptors.[2][3]
See also
References
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- JWH cannabinoids
- Aminoalkylindoles
- Naphthoylindoles
- Morpholines
- Designer drugs
- Cannabinoid stubs